Skip to content
Clinical Trials – home
CzechiaBack to Czechia

Clinical trials in Ostrava – page 12

282 clinical trials in Ostrava, Czechia across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

CzechiaOur site in CzechiaKlinickeTesty.cz(opens in a new tab)
Ostrava at a glance
282
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

282 trials in Ostrava

Open in trial search

Plasma cell myeloma

Not yet recruiting

Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Autoimmune hepatitis

Not yet recruiting

A Phase 2/3 Randomized Double‑Blind Study of Inebilizumab for Safety and Tolerability in Patients with Autoimmune Hepatitis

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Inebilizumab
  • Sponsor:Amgen Inc.

Chronic lymphocytic leukaemia+2

Not yet recruiting

Clinical Trial of Human Normal Immunoglobulin to Prevent Infections in Patients with Secondary Antibody Deficiency due to CLL, Multiple Myeloma or Non‑Hodgkin Lymphoma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:Grifols Therapeutics LLC

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Lung assist device therapy

Not yet recruiting

Comparing low-dose and standard-dose argatroban or enoxaparin to prevent blood clots in patients with heart or lung failure receiving extracorporeal membrane oxygenation.

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Enoxaparin Sodium
  • Sponsor:Fakultni Nemocnice Ostrava

A Study of Linvoseltamab Alone and Linvoseltamab with Carfilzomib Compared to Standard Treatment in Adults with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Aciclovir
  • Sponsor:Regeneron Pharmaceuticals Inc.

Fallopian tube cancer+1

Not yet recruiting

Study of TORL-1-23 and pegfilgrastim in women with advanced platinum-resistant ovarian, peritoneal, or fallopian tube cancer expressing CLDN6

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Glatiramer Acetate
  • Sponsor:Torl Biotherapeutics LLC

Cardiac failure

Not yet recruiting

Study on COR-1167 for Patients with Worsening Heart Failure

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Sponsor:Corteria Pharmaceuticals

Diarrhoea

Not yet recruiting

Study on Allogeneic Faecal Microbiota for Treating Antibiotic-Related Diarrhea in Critically Ill Patients

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Faecal Microbiota, Pooled
  • Sponsor:Fakultni Nemocnice Kralovske Vinohrady

Neoplasm malignant

Not yet recruiting

Study of Brentuximab Vedotin with Drug Combination for Untreated CD30-expressing Peripheral T-cell Lymphoma Patients

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Brentuximab Vedotin
  • Sponsor:Kooperativni Lymfomova Skupina z.s.

Narcolepsy

Not yet recruiting

Study on TAK-861 for Treating Narcolepsy with Cataplexy in Patients

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:N-{(2S,3R)-4,4-Difluoro-1-(2-Hydroxy-2-Methylpropanoyl)-2-[(2,3',5'-Trifluoro[1,1'-Biphenyl]-3-Yl)Methyl]Pyrrolidin-3-Yl}Ethanesulfonamide
  • Sponsor:Takeda Development Center Americas Inc.

Neoplasm malignant

Not yet recruiting

Study on the Effectiveness and Safety of Luveltamab Tazevibulin Compared to Chemotherapy in Women with Relapsed Platinum-resistant Ovarian Cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Sutro Biopharma Inc.

Other cities in Czechia

The busiest research cities in the country

All 158 cities in Czechia

Clinical research in Ostrava

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on metastatic prostate cancer and lung cancer treatments. Studies include evaluation of novel therapies for multiple myeloma and various forms of leukemia.

  • Prostate Cancer Treatment Advances
  • Small Cell Lung Cancer Therapy
  • Blood Cancer Interventions

Multiple collaborative studies exploring targeted therapies and combination treatments for advanced-stage cancers.

02 Immunology and Inflammatory Diseases

Research targeting inflammatory bowel diseases, including studies on Crohn's Disease and ulcerative colitis. Investigations into novel treatments for psoriatic arthritis.

  • Inflammatory Bowel Disease Management
  • Autoimmune Conditions
  • Chronic Inflammatory Disorders

Comprehensive evaluation of innovative therapeutic approaches for chronic inflammatory conditions.

03 Cardiovascular and Infectious Diseases

Studies examining cardiovascular disease treatments and prevention strategies. Research on bacterial infections and antimicrobial therapies, including trials for complicated urinary tract infections.

  • Heart Disease Prevention
  • Infection Management
  • Antibiotic Optimization

Advanced research combining preventive approaches with targeted therapeutic interventions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.